KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Edwards Lifesciences (EW) Accumulated Depreciation & Amortization (2016 - 2025)

Edwards Lifesciences has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $156.6 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 0.9% year-over-year to $156.6 million; the TTM value through Dec 2025 reached $156.6 million, up 0.9%, while the annual FY2025 figure was $156.6 million, 0.9% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $156.6 million at Edwards Lifesciences, up from $155.2 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $156.6 million in Q4 2025 and troughed at $139.6 million in Q4 2022.
  • A 4-year average of $149.1 million and a median of $150.0 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: rose 7.11% in 2024 and later rose 0.9% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $139.6 million in 2022, then increased by 3.8% to $144.9 million in 2023, then rose by 7.11% to $155.2 million in 2024, then rose by 0.9% to $156.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for EW at $156.6 million in Q4 2025, $155.2 million in Q4 2024, and $144.9 million in Q4 2023.